Form 6-K Silence Therapeutics For: Sep 29

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of September 2022

 

 

 

Commission File Number: 001-39487

 

 

 

Silence Therapeutics plc

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

72 Hammersmith Road

London W14 8TH

United Kingdom

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒           Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

---

 

Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated September 29, 2022.

 

EXHIBIT INDEX

 

 

---

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Date: September 29, 2022

 

ATTACHMENTS / EXHIBITS

EX-99.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Salary.com Celebrates 25 Years of Innovation
• Nurse Well-Being the Focus of Engage, Powered By ENA-Golisano Children's Hospital Partnership
• University of Washington School of Medicine AIMS Center and Concert Health to Scale Telepsychiatry Collaborative Care for Complex Psychiatric Disorders